Dimdazenil: First Approval.
Drugs
; 84(5): 607-611, 2024 May.
Article
de En
| MEDLINE
| ID: mdl-38546956
ABSTRACT
Dimdazenil (Junoenil®) is a small-molecule, oral, partial positive allosteric modulator of the gamma-aminobutyric acid (GABA)A receptor that is being developed by Zhejiang Jingxin Pharmaceutical in collaboration with Evotec for the treatment of insomnia. Dimdazenil is designed to overcome issues associated with full GABAA receptor agonists, such as tolerance, withdrawal symptoms and associated adverse effects. On 29 November 2023, dimdazenil oral capsules received approval in China for the short-term treatment of insomnia. This article summarizes the milestones in the development of dimdazenil leading to this first approval for insomnia.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Agrément de médicaments
/
Troubles de l'endormissement et du maintien du sommeil
Limites:
Humans
Pays/Région comme sujet:
Asia
Langue:
En
Journal:
Drugs
Année:
2024
Type de document:
Article
Pays d'affiliation:
Nouvelle-Zélande